LU83620A1 - Procede de preparation de solutions de lipoproteines a partir de residus de delipidation des plasmas et serums sanguins,produits nouveaux obtenus et leurs applications - Google Patents
Procede de preparation de solutions de lipoproteines a partir de residus de delipidation des plasmas et serums sanguins,produits nouveaux obtenus et leurs applications Download PDFInfo
- Publication number
- LU83620A1 LU83620A1 LU83620A LU83620A LU83620A1 LU 83620 A1 LU83620 A1 LU 83620A1 LU 83620 A LU83620 A LU 83620A LU 83620 A LU83620 A LU 83620A LU 83620 A1 LU83620 A1 LU 83620A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- solutions
- lipoproteins
- stable
- sera
- lipoprotein
- Prior art date
Links
- 102000004895 Lipoproteins Human genes 0.000 title claims description 41
- 108090001030 Lipoproteins Proteins 0.000 title claims description 41
- 238000000034 method Methods 0.000 title claims description 24
- 210000002381 plasma Anatomy 0.000 title claims description 17
- 210000002966 serum Anatomy 0.000 title claims description 17
- 230000008569 process Effects 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title claims description 6
- 230000015961 delipidation Effects 0.000 title claims description 3
- 239000000243 solution Substances 0.000 claims description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 28
- 239000011780 sodium chloride Substances 0.000 claims description 19
- 239000000872 buffer Substances 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 230000002421 anti-septic effect Effects 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 9
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 7
- 230000002255 enzymatic effect Effects 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 5
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 claims description 4
- YFNXWBPNBVLTMB-UHFFFAOYSA-N 2-bromo-2-nitro-1,4-dioxane Chemical compound [O-][N+](=O)C1(Br)COCCO1 YFNXWBPNBVLTMB-UHFFFAOYSA-N 0.000 claims description 3
- 102000006410 Apoproteins Human genes 0.000 claims description 3
- 108010083590 Apoproteins Proteins 0.000 claims description 3
- 229960003260 chlorhexidine Drugs 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 235000010292 orthophenyl phenol Nutrition 0.000 claims description 3
- 239000004306 orthophenyl phenol Substances 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 230000037356 lipid metabolism Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims 2
- 239000006193 liquid solution Substances 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- USQRRBLDGCWFEY-UHFFFAOYSA-N 2-amino-1,4-dihydroxy-3-(hydroxymethyl)-3-methylbutane-2-sulfonic acid Chemical compound CC(CO)(CO)C(N)(CO)S(O)(=O)=O USQRRBLDGCWFEY-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- 229910002019 Aerosil® 380 Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- XVBRCOKDZVQYAY-UHFFFAOYSA-N bronidox Chemical compound [O-][N+](=O)C1(Br)COCOC1 XVBRCOKDZVQYAY-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- NHWZQIYTQZEOSJ-UHFFFAOYSA-N carbonic acid;phosphoric acid Chemical compound OC(O)=O.OP(O)(O)=O NHWZQIYTQZEOSJ-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8019935A FR2490228A1 (fr) | 1980-09-16 | 1980-09-16 | Procede de preparation de solutions de lipoproteines a partir de residus de delipidation des plasmas et serums sanguins et produits ainsi obtenus |
| FR8019935 | 1980-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU83620A1 true LU83620A1 (fr) | 1982-04-14 |
Family
ID=9245983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU83620A LU83620A1 (fr) | 1980-09-16 | 1981-09-08 | Procede de preparation de solutions de lipoproteines a partir de residus de delipidation des plasmas et serums sanguins,produits nouveaux obtenus et leurs applications |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0048209B1 (it) |
| BE (1) | BE890338A (it) |
| DE (1) | DE3173450D1 (it) |
| ES (1) | ES505516A0 (it) |
| FR (1) | FR2490228A1 (it) |
| IT (1) | IT1144864B (it) |
| LU (1) | LU83620A1 (it) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2678436B2 (ja) * | 1986-02-18 | 1997-11-17 | 三信工業 株式会社 | 船外機用オイルポンプの自動エアー抜き装置 |
| US4658453A (en) * | 1986-04-14 | 1987-04-21 | Dennis Boyd | Wave-retarding waterbed mattress |
| DE4317085A1 (de) * | 1993-05-21 | 1994-11-24 | Forsch Kurt Schwabe Meinsberg | Verfahren zur Kalibrierung elektrochemischer Meßeinrichtungen und Vorrichtung zur Durchführung des Verfahrens |
| US6193484B1 (en) | 1998-10-21 | 2001-02-27 | Scroll Technologies | Force-fit scroll compressor assembly |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3382227A (en) * | 1967-01-30 | 1968-05-07 | Pentex Inc | Blood protein fractionation employing 2-ethoxy-6, 9-diamino-acridine-lactate |
| DE2324386C2 (de) * | 1973-05-14 | 1975-07-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Wäßriger Cholestrin-Standard |
| US3859047A (en) * | 1973-05-29 | 1975-01-07 | Hoffmann La Roche | Standard for serum cholesterol determination |
| US3998946A (en) * | 1975-04-23 | 1976-12-21 | The Regents Of The University Of Minnesota | Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same |
| US4045176A (en) * | 1975-06-13 | 1977-08-30 | Proksch Gary J | Preparation of optically clear serum |
| US4216117A (en) * | 1978-05-15 | 1980-08-05 | Bonderman Dean P | Lipoprotein diluent or solution and method useful in the preparation of assay reference materials |
| US4210557A (en) * | 1978-12-15 | 1980-07-01 | Beckman Instruments, Inc. | Non-high density lipoprotein precipitant |
| US4290774A (en) * | 1980-01-07 | 1981-09-22 | Miles Laboratories, Inc. | Purification of lipoprotein cholesterol for use as a cholesterol reference material |
-
1980
- 1980-09-16 FR FR8019935A patent/FR2490228A1/fr active Granted
-
1981
- 1981-09-08 LU LU83620A patent/LU83620A1/fr unknown
- 1981-09-14 BE BE0/205952A patent/BE890338A/fr not_active IP Right Cessation
- 1981-09-15 EP EP81401434A patent/EP0048209B1/fr not_active Expired
- 1981-09-15 ES ES505516A patent/ES505516A0/es active Granted
- 1981-09-15 DE DE8181401434T patent/DE3173450D1/de not_active Expired
- 1981-09-16 IT IT68210/81A patent/IT1144864B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| IT1144864B (it) | 1986-10-29 |
| EP0048209B1 (fr) | 1986-01-08 |
| FR2490228B1 (it) | 1983-08-05 |
| BE890338A (fr) | 1982-03-15 |
| ES8303441A1 (es) | 1983-02-01 |
| DE3173450D1 (en) | 1986-02-20 |
| ES505516A0 (es) | 1983-02-01 |
| EP0048209A1 (fr) | 1982-03-24 |
| IT8168210A0 (it) | 1981-09-16 |
| FR2490228A1 (fr) | 1982-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Steinert et al. | Characterization of a class of cationic proteins that specifically interact with intermediate filaments. | |
| Ul | Isoelectric points and conformation of proteins: I. Effect of urea on the behavior of some proteins in isoelectric focusing | |
| ABE et al. | Isolation and characterization of presynaptically acting neurotoxins from the venom of Bungarus snakes | |
| CH647871A5 (fr) | Reactif de lysat d'amibocytes de limule. | |
| EP0115627B1 (en) | Enhancement of intranasal absorption of calcitonin by formulation with surfactants | |
| FR2431701A1 (fr) | Procede de preparation d'une composition biologique a utiliser comme temoin de reference dans l'analyse diagnostique et composition obtenue par le procede | |
| Cotten et al. | Novobiocin precipitates histones at concentrations normally used to inhibit eukaryotic type II topoisomerase | |
| Lenaz et al. | Mitochondrial structural protein I: Methods of preparation and purification: Characterization by gel electrophoresis | |
| EP0322262B1 (fr) | Protéine basique dénommée phospholipase A2 isolée de venin de serpent de la famille des élapidés et sa séquence en amino-acides, dérivés et fragments de ladite protéine, leur procédé d'obtention, compositions thérapeutiques et agents de diagnostic contenant ladite protéine et/ou ses dérivés et/ou ses fragments | |
| US20150376230A1 (en) | Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations | |
| Reh et al. | Isolation of alpha-1-antitrypsin from human plasma by partitioning in aqueous biphasic systems of polyethyleneglycol–phosphate | |
| EP0048209B1 (fr) | Procédé de préparation de solutions de lipoprotéines à partir de résidus de délipidation des plasmas et sérums sanguins, produits nouveaux obtenus, et leurs applications | |
| FR2489690A1 (fr) | Procede d'obtention de la fraction ovomucoide et d'un extrait d'ovomucoide de l'oeuf de caille, produits ainsi obtenus et leur application a titre de medicament | |
| CH626808A5 (it) | ||
| FR2513640A1 (fr) | Procede de preparation d'une composition de gamma globuline qui convient pour l'administration intraveineuse et composition obtenue par ce procede | |
| OSAKI | INVESTIGATION ON CAERULOPLASMIN I. PURIFICATION AND SOME PHYSICO-CHEMICAL PROPERTIES OF CAERULOPLASMIN | |
| EP0683791A1 (fr) | Composition aqueuse proteinique, glycoproteine contenue, procede d'obtention et utilisations | |
| Brenowitz et al. | Assembly and calcium-induced cooperativity of Limulus IV hemocyanin: a model system for analysis of structure-function relationships in the absence of subunit heterogeneity | |
| FR2513766A1 (fr) | Procedes et reactifs de separation selective des lipoproteines de faible densite ldl et de quantification de leurs composants | |
| Walker et al. | The molecular mechanisms of heparin action: III. The anticoagulant properties of polyanetholesulfonate | |
| FR2816213A1 (fr) | Medicament anti-inflammatoire et cicatrisant | |
| FR2644064A1 (fr) | Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant | |
| Hozumi | Structural aspects of skeletal muscle F-actin as studied by tryptic digestion: evidence for a second nucleotide interacting site | |
| FR2495184A1 (fr) | Procede et reactif pour clarifier un liquide biologique trouble | |
| Middlebrook | The N-terminal residues of bovine plasma clot |